麻豆传媒

Meeting Coverage >

ASHP

Cost Savings With Pharmacist-Driven Substitutions of Oncology Biosimilars

Regional clinical pharmacists helped community oncology practices navigate logistics, financials

Drug-Diversion Program Cut Controlled-Substance Discrepancies at Mount Sinai

A daily audit of EHR and dispensing machines revealed documentation mistakes, other errors

Research on the Effects of Posture on Drug Absorption Lacking

Major gaps in methodology revealed in studies evaluating posture and pharmacokinetics

Beware Flu and COVID Vax Mix-Ups and Other Medication Errors

Medication safety group previews new best practices for next year

Digital HTN, Diabetes Monitoring Program a Boon for Patients

Program reports growth and better outcomes

U.S. Dragging Its Feet on Biosimilar Approvals, Pharmacist Says

Introduction of biosimilars falling behind that of other countries

The ASHP Wants to Stop White Bagging on Prescription Drugs

This practice "jeopardizes patient care," says ASHP official

Hospitals Confront New Accreditation Standards to Come

Small, rural sites may be uniquely affected by Joint Commission standards expected in 2022

Efforts Needed to De-Escalate Use of Inhaled Corticosteroids in COPD

Clinicians are not always following the guidelines

C. Difficile Inpatient Stays Long, Costly

LAS VEGAS -- Among the many factors that contribute to the burgeoning costs associated with Clostridium difficile infections are long hospital stays, particularly in intensive care units, and the need for multiple specialist consultations, a chart review determined.

Melanoma Tx Ups Survival, but Very Pricey

LAS VEGAS -- The oral BRAF inhibitor vemurafenib (Zelboraf) increased survival in patients with metastatic melanoma, but the cost may not justify its use in a state Medicaid program, an analysis suggested.

ALS Drug Gets Review for VA Coverage

LAS VEGAS -- Riluzole (Rilutek) should remain on the Veterans Administration formulary as a treatment for patients with amyotrophic lateral sclerosis, despite having only modest benefits and considerable cost, a researcher said here.

Enbrel Best Buy Among Anti-TNFs

LAS VEGAS -- The tumor necrosis factor inhibitor etanercept (Enbrel) was more cost-effective for the treatment of rheumatoid arthritis than were two other biologic agents in this class, a budget impact analysis found.